NEIRO / FDUSD

NEIRO / USDT

NEIRO / TRY

NEIRO / USDC

MUBARAK / USDC

MUBARAK / USDT

KAITO / BNB

1000CAT / BNB

1000CAT / FDUSD

1000CAT / USDT

SYN / USDT

SYN / USDC

BABY / EUR

ACT / EUR

BABY / FDUSD

CATI / FDUSD

CATI / TRY

ACT / FDUSD

ACH / BTC

CATI / USDC

MAX INDIA LTD

INSPIRISYS SOLUTIONS LTD

DYNAMIC CABLES LIMITED

GACM TECHNO LTD

LINC LIMITED

INFOBEANS TECHNO. LTD.

CENTUM ELECTRONICS LTD

TANLA PLATFORMS LIMITED

CARE RATINGS LIMITED

SUVEN LIFE SCIENCES LTD

BANNARI AMMAN SPINNING

DMCC SPECIALITY CHEMICALS

RAPPID VALVES (INDIA) LTD

GP ECO SOLUTIONS INDIA L

GANESH HOUSING CORP LTD

THE ANUP ENGINEERING LTD

KRSNAA DIAGNOSTICS LTD

WOL 3D INDIA LIMITED

UNITED HEAT TRANSFER LTD

PRANIK LOGISTICS LIMITED

Click here to get full coverage on Suven Pharmaceuticals Faces Market Sentiment Shift Amid Profit Decline Concerns - MarketsMojo

Suven Pharmaceuticals Faces Market Sentiment Shift Amid Profit Decline Concerns  MarketsMojo

Suven Pharmaceuticals Faces Market Sentiment Shift Amid Profit Decline Concerns - MarketsMojo

Click here to get full coverage on Sunil Singhania, Prashant Jain invest in Suven Life preferential issue; stock jumps 12% - CNBC TV18

Sunil Singhania, Prashant Jain invest in Suven Life preferential issue; stock jumps 12%  CNBC TV18

Sunil Singhania, Prashant Jain invest in Suven Life preferential issue; stock jumps 12% - CNBC TV18

Click here to get full coverage on Suven Life Sciences reports consolidated net loss of Rs 43.94 crore in the March 2025 quarter - Business Standard

Suven Life Sciences reports consolidated net loss of Rs 43.94 crore in the March 2025 quarter  Business Standard

Suven Life Sciences reports consolidated net loss of Rs 43.94 crore in the March 2025 quarter - Business Standard

Click here to get full coverage on Suven Life Sciences Q4 loss widens to Rs 43.95 cr - theweek.in

Suven Life Sciences Q4 loss widens to Rs 43.95 cr  theweek.in

Suven Life Sciences Q4 loss widens to Rs 43.95 cr - theweek.in

Click here to get full coverage on Suven Life Sciences' Q4 net loss widens over 65 pc as revenue falls 39 pc - lokmattimes.com

Suven Life Sciences' Q4 net loss widens over 65 pc as revenue falls 39 pc  lokmattimes.com

Suven Life Sciences' Q4 net loss widens over 65 pc as revenue falls 39 pc - lokmattimes.com

Click here to get full coverage on Suven Life Sciences divulges new muscarinic M4 receptor PAMs - BioWorld MedTech

Suven Life Sciences divulges new muscarinic M4 receptor PAMs  BioWorld MedTech

Suven Life Sciences divulges new muscarinic M4 receptor PAMs - BioWorld MedTech

Click here to get full coverage on Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y - Moneycontrol

Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y  Moneycontrol

Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y - Moneycontrol

Click here to get full coverage on Suven Life Sciences Share Price Today Up 8% - Equitymaster

Suven Life Sciences Share Price Today Up 8%  Equitymaster

Suven Life Sciences Share Price Today Up 8% - Equitymaster

Click here to get full coverage on Suven Pharmaceuticals is now Cohance Lifesciences - Indian Pharma Post

Suven Pharmaceuticals is now Cohance Lifesciences  Indian Pharma Post

Suven Pharmaceuticals is now Cohance Lifesciences - Indian Pharma Post

Click here to get full coverage on Suven Pharmaceuticals rebrands as Cohance Lifesciences - bestmediainfo.com

Suven Pharmaceuticals rebrands as Cohance Lifesciences  bestmediainfo.com

Suven Pharmaceuticals rebrands as Cohance Lifesciences - bestmediainfo.com

Click here to get full coverage on Suven Pharmaceuticals Acquires Controlling Stake in NJ Bio to Expand ADC Market Reach - Precedence Research

Suven Pharmaceuticals Acquires Controlling Stake in NJ Bio to Expand ADC Market Reach  Precedence Research

Suven Pharmaceuticals Acquires Controlling Stake in NJ Bio to Expand ADC Market Reach - Precedence Research

Click here to get full coverage on Advent-owned Suven Pharma to buy majority stake in NJ Bio for $64 mn - VCCircle

Advent-owned Suven Pharma to buy majority stake in NJ Bio for $64 mn  VCCircle

Advent-owned Suven Pharma to buy majority stake in NJ Bio for $64 mn - VCCircle

Click here to get full coverage on Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn - The Economic Times

Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn  The Economic Times

Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn - The Economic Times

Click here to get full coverage on Suven Pharmaceuticals rebrands as Cohance Lifesciences - Adgully.com

Suven Pharmaceuticals rebrands as Cohance Lifesciences  Adgully.com

Suven Pharmaceuticals rebrands as Cohance Lifesciences - Adgully.com

Click here to get full coverage on Smallcap stock surges 15%, hits record high today; what's behind the rally? - Business Standard

Smallcap stock surges 15%, hits record high today; what's behind the rally?  Business Standard

Smallcap stock surges 15%, hits record high today; what's behind the rally? - Business Standard

Click here to get full coverage on Suven Pharmaceuticals Shows Trend Reversal Amid Broader Market Resilience - MarketsMojo

Suven Pharmaceuticals Shows Trend Reversal Amid Broader Market Resilience  MarketsMojo

Suven Pharmaceuticals Shows Trend Reversal Amid Broader Market Resilience - MarketsMojo

Click here to get full coverage on Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle? - Moneycontrol

Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle?  Moneycontrol

Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle? - Moneycontrol

Click here to get full coverage on Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio - CNBC TV18

Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio  CNBC TV18

Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio - CNBC TV18

Click here to get full coverage on Suven Pharma acquires majority stake in US-based NJ Bio - Moneycontrol

Suven Pharma acquires majority stake in US-based NJ Bio  Moneycontrol

Suven Pharma acquires majority stake in US-based NJ Bio - Moneycontrol

Click here to get full coverage on Suven Pharma to acquire majority stake in US-based NJ Bio - Business Standard

Suven Pharma to acquire majority stake in US-based NJ Bio  Business Standard

Suven Pharma to acquire majority stake in US-based NJ Bio - Business Standard

Click here to get full coverage on Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders - Clinical Trials Arena

Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders  Clinical Trials Arena

Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders - Clinical Trials Arena

Click here to get full coverage on In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson's Disease - PR Newswire

In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson's Disease  PR Newswire

In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson's Disease - PR Newswire

Click here to get full coverage on Suven Pharma Eyes $1-Billion Revenue By 2030, Driven By CDMO Expansion - NDTV Profit

Suven Pharma Eyes $1-Billion Revenue By 2030, Driven By CDMO Expansion  NDTV Profit

Suven Pharma Eyes $1-Billion Revenue By 2030, Driven By CDMO Expansion - NDTV Profit

Click here to get full coverage on Suven Pharma sets sights on M&As to scale up tech expertise & order book - The Economic Times

Suven Pharma sets sights on M&As to scale up tech expertise & order book  The Economic Times

Suven Pharma sets sights on M&As to scale up tech expertise & order book - The Economic Times

Click here to get full coverage on Suven Pharmaceuticals renamed as Cohance Lifesciences - Business Standard

Suven Pharmaceuticals renamed as Cohance Lifesciences  Business Standard

Suven Pharmaceuticals renamed as Cohance Lifesciences - Business Standard

Click here to get full coverage on Suven to Divi’s: Indian CDMOs seize opportunity in pivot away from China amid global trade tensions - Moneycontrol

Suven to Divi’s: Indian CDMOs seize opportunity in pivot away from China amid global trade tensions  Moneycontrol

Suven to Divi’s: Indian CDMOs seize opportunity in pivot away from China amid global trade tensions - Moneycontrol

Click here to get full coverage on Suven Pharma to acquire 56% stake in U.S. firm NJ Bio for $64.4 million - The Hindu

Suven Pharma to acquire 56% stake in U.S. firm NJ Bio for $64.4 million  The Hindu

Suven Pharma to acquire 56% stake in U.S. firm NJ Bio for $64.4 million - The Hindu

Click here to get full coverage on Suven to acquire controlling stake in Sapala Organics - Pharmaceutical Technology

Suven to acquire controlling stake in Sapala Organics  Pharmaceutical Technology

Suven to acquire controlling stake in Sapala Organics - Pharmaceutical Technology

Click here to get full coverage on Suven Pharmaceuticals renamed as Cohance Lifesciences - Capital Market

Suven Pharmaceuticals renamed as Cohance Lifesciences  Capital Market

Suven Pharmaceuticals renamed as Cohance Lifesciences - Capital Market

Click here to get full coverage on Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million - Indian Pharma Post

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million  Indian Pharma Post

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million - Indian Pharma Post

Click here to get full coverage on Goldman Sachs initiates coverage on Suven Pharma and Piramal Pharma - Moneycontrol

Goldman Sachs initiates coverage on Suven Pharma and Piramal Pharma  Moneycontrol

Goldman Sachs initiates coverage on Suven Pharma and Piramal Pharma - Moneycontrol

Click here to get full coverage on Suven Pharmaceuticals Addresses Delay in Auditor Appointment Disclosure - TipRanks

Suven Pharmaceuticals Addresses Delay in Auditor Appointment Disclosure  TipRanks

Suven Pharmaceuticals Addresses Delay in Auditor Appointment Disclosure - TipRanks

Click here to get full coverage on Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene - The Economic Times

Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene  The Economic Times

Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene - The Economic Times

Click here to get full coverage on Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant - Indian Pharma Post

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant  Indian Pharma Post

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant - Indian Pharma Post

Click here to get full coverage on Suven Pharmaceuticals Receives NSE Caution Over Disclosure Delay - TipRanks

Suven Pharmaceuticals Receives NSE Caution Over Disclosure Delay  TipRanks

Suven Pharmaceuticals Receives NSE Caution Over Disclosure Delay - TipRanks

Click here to get full coverage on Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug - Moneycontrol

Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug  Moneycontrol

Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug - Moneycontrol

Click here to get full coverage on Suven Pharmaceuticals Releases Q3FY25 Conference Call Recording - TipRanks

Suven Pharmaceuticals Releases Q3FY25 Conference Call Recording  TipRanks

Suven Pharmaceuticals Releases Q3FY25 Conference Call Recording - TipRanks

Click here to get full coverage on Suven Pharma, Divis, Syngene: Why Macquarie is betting big on Indian pharma - Business Standard

Suven Pharma, Divis, Syngene: Why Macquarie is betting big on Indian pharma  Business Standard

Suven Pharma, Divis, Syngene: Why Macquarie is betting big on Indian pharma - Business Standard

Click here to get full coverage on 'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman - Moneycontrol

'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman  Moneycontrol

'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman - Moneycontrol

Click here to get full coverage on Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant - Indian Pharma Post

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant  Indian Pharma Post

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant - Indian Pharma Post

Click here to get full coverage on Hyderabad-based drug manufacturer Suven to acquire majority stake in NJ Bio for $64 million - The New Indian Express

Hyderabad-based drug manufacturer Suven to acquire majority stake in NJ Bio for $64 million  The New Indian Express

Hyderabad-based drug manufacturer Suven to acquire majority stake in NJ Bio for $64 million - The New Indian Express

Click here to get full coverage on NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences - Business Standard

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences  Business Standard

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences - Business Standard

Click here to get full coverage on Suven Life spurts on initiating Phase-1 of clinical trial in US - Business Standard

Suven Life spurts on initiating Phase-1 of clinical trial in US  Business Standard

Suven Life spurts on initiating Phase-1 of clinical trial in US - Business Standard

Click here to get full coverage on Suven Pharma appoints Declan Ryan as CCO - Indian Pharma Post

Suven Pharma appoints Declan Ryan as CCO  Indian Pharma Post

Suven Pharma appoints Declan Ryan as CCO - Indian Pharma Post

Click here to get full coverage on Advent-controlled Suven Pharma appoints former Piramal exec as chairman - VCCircle

Advent-controlled Suven Pharma appoints former Piramal exec as chairman  VCCircle

Advent-controlled Suven Pharma appoints former Piramal exec as chairman - VCCircle

Click here to get full coverage on Suven Pharma shares in focus after Q3 profit jumps 78% YoY, revenue up 40% - The Economic Times

Suven Pharma shares in focus after Q3 profit jumps 78% YoY, revenue up 40%  The Economic Times

Suven Pharma shares in focus after Q3 profit jumps 78% YoY, revenue up 40% - The Economic Times

Click here to get full coverage on Cohance Lifesciences, The New Identity Of Suven Pharmaceuticals - Passionate In Marketing

Cohance Lifesciences, The New Identity Of Suven Pharmaceuticals  Passionate In Marketing

Cohance Lifesciences, The New Identity Of Suven Pharmaceuticals - Passionate In Marketing

Click here to get full coverage on Suven Life Sciences shares ended 10% higher after this important announcement - CNBC TV18

Suven Life Sciences shares ended 10% higher after this important announcement  CNBC TV18

Suven Life Sciences shares ended 10% higher after this important announcement - CNBC TV18

Click here to get full coverage on Goldman Sachs sees up to 28% upside in two 'consensus buy' pharma stocks - CNBC TV18

Goldman Sachs sees up to 28% upside in two 'consensus buy' pharma stocks  CNBC TV18

Goldman Sachs sees up to 28% upside in two 'consensus buy' pharma stocks - CNBC TV18

Click here to get full coverage on Rising Bags Private Equity Investment As Parent Suven Pharma Sells Stake - insights.citeline.com

Rising Bags Private Equity Investment As Parent Suven Pharma Sells Stake  insights.citeline.com

Rising Bags Private Equity Investment As Parent Suven Pharma Sells Stake - insights.citeline.com

Click here to get full coverage on Suven Pharmaceuticals rebrands as Cohance Lifesciences to reflect strategic transformation - MediaBrief

Suven Pharmaceuticals rebrands as Cohance Lifesciences to reflect strategic transformation  MediaBrief

Suven Pharmaceuticals rebrands as Cohance Lifesciences to reflect strategic transformation - MediaBrief

Click here to get full coverage on Macquarie initiates outperform rating on 4 Indian pharma stocks, sees 19-35% upside. Here's why - Mint

Macquarie initiates outperform rating on 4 Indian pharma stocks, sees 19-35% upside. Here's why  Mint

Macquarie initiates outperform rating on 4 Indian pharma stocks, sees 19-35% upside. Here's why - Mint

Click here to get full coverage on NCLT sanctions amalgamation of Cohance Lifesciences into Suven Pharmaceuticals - Times of India

NCLT sanctions amalgamation of Cohance Lifesciences into Suven Pharmaceuticals  Times of India

NCLT sanctions amalgamation of Cohance Lifesciences into Suven Pharmaceuticals - Times of India

Click here to get full coverage on Suven Pharmaceuticals names Vivek Sharma as executive chairman - The Economic Times

Suven Pharmaceuticals names Vivek Sharma as executive chairman  The Economic Times

Suven Life Sciences Limited (SUVEN)

Price Chart

Key Statistics

Technicals

About SUVEN

Latest News

Suven Pharmaceuticals Faces Market Sentiment Shift Amid Profit Decline Concerns - MarketsMojo

Sunil Singhania, Prashant Jain invest in Suven Life preferential issue; stock jumps 12% - CNBC TV18

Suven Life Sciences reports consolidated net loss of Rs 43.94 crore in the March 2025 quarter - Business Standard

Advanced Charts

Top Gainers

Top Losers